Neostem Obtains Exclusive Worldwide License For Innovative Stem Cell Technology And Applications To

< BACK TO SCIENTIFIC starstarstarstarstar   Science - Scientific Press Release
5th May 2009, 12:12am - Views: 417





Science Information Technology NeoStem, Inc. 1 image







NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology

and Applications to Heal Chronic Wounds


NEW YORK, May 4 /PRNewswire-AsiaNet/ --


    NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease

collection, processing and long-term storage of adult stem cells for future

medical need, announced today it has signed an agreement to license the exclusive

worldwide rights to an innovative product and procedure using autologous bone

marrow-derived stem cells to promote the healing of chronic wounds. 

    The licensed technology, with pending patent applications, has been developed

by Vincent Falanga, M.D., Chairman of the Department of Dermatology and Skin

Surgery at Roger Williams Medical Center, Providence, R.I.  Dr. Falanga is also

Professor of Dermatology and Biochemistry at Boston University School of

Medicine, a Fellow of the American College of Physicians, and a past President of

the Wound Healing Society, the leading scientific organization focused on this

specialty. 


    Dr. Falanga’s stem cell product under development, Primcel, is a mesenchymal

stem cell (MSC) product.  Early clinical studies indicate that Primcel can be

used to accelerate or jump start healing of chronic wounds.  Dr. Falanga’s work

seeks to develop a prepackaged product, ready for physician use in a clinical

setting, consisting of three applications over a 12-week period. 


    Dr. Robin Smith, CEO of NeoStem, said, “We are very pleased to sign this

agreement with Dr. Falanga.  Acquisition of the exclusive worldwide rights to

this innovative wound healing technology will help advance NeoStem as a leader in

the field of stem-cell tissue regeneration.”  


    Dr. Smith added, “In October 2008, we announced that the U.S. Department of

Defense appropriated $800,000 in funds for NeoStem to evaluate the potential use

of adult stem cell therapy for treating wounds suffered by members of the U.S.

military and first responders.  We hope this effort will lead to groundbreaking

medical findings that ultimately save troops from amputations and immobilization

from injuries sustained while fighting for our country.  The award is required to

be distributed to NeoStem by October 2010 and will be in the net amount of

$681,000.”


    “Moreover,” she continued, “chronic wounds are a major unmet medical need for

both civilians and military personnel. For example, in 2003, in the United

States, 120,000 diabetic patients required treatment for a chronic wound and

75,000 required lower extremity amputations related to unhealed wounds, costing

the healthcare system in excess of $4 billion.  Radiation exposure, severe burns,

and crush injuries of the bone are other causes of chronic open wounds. Our goal,

through the DOD grant, is to determine if there are multiple sources of

autologous stem cells to effectively treat wounds, and Dr. Falanga’s bone marrow

procedure is an important step in that direction.  Other procedures to be

explored may use mobilized peripheral blood stem cells or VSELs, for example.”  


    About NeoStem, Inc. 

    NeoStem is developing a network of adult stem cell collection centers that

are focused on enabling people to donate and store their own (autologous) stem

cells when they are young and healthy for their personal use in times of future

medical need. The Company has also entered into research and development through

the acquisition of a worldwide exclusive license to technology to identify and

isolate VSELs (very small embryonic-like stem cells), which have been shown to

have several physical characteristics that are generally found in embryonic stem

Science Information Technology NeoStem, Inc. 2 image

cells and is pursuing other technologies to advance its position in the field of

stem cell tissue regeneration.




    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995. Forward-looking statements

reflect management's current expectations, as of the date of this press release,

and involve certain risks and uncertainties. The Company's actual results,

including the realization of potential benefits from the acquisition of its new

licensed technology, could differ materially from those anticipated in these

forward-looking statements as a result of various factors. Factors that could

cause future results to materially differ from the recent results or those

projected in forward-looking statements include the "Risk Factors" described in

the Company's Annual Report on Form 10-K for its fiscal year ended December 31,

2008 and the Company's other periodic filings with the Securities and Exchange

Commission. The Company's further development is highly dependent on future

medical and research developments and market acceptance, which is outside its

control.


  CONTACT:

    NeoStem, Inc.

    Robin Smith, Chief Executive Officer

    T: 212-584-4180

    E: rsmith@neostem.com

       www.neostem.com


  SOURCE: NeoStem, Inc.





Translations:

   Chinese - Traditional (http://asianetnews.net/Download.asp?ID=124863)









To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article